Genmab — Marts 2018

[polle1]

God morgen i sneen

[rex_pacis]

God morgen

[E_L]

god morgen. A bit surprised to see this Ofa study on "Pemphigus Vulgaris" set to 'completed' only now https://clinicaltrials.gov/ct2/show/NCT01920477?term=daratumumab+OR+ofatumumab+OR+tisotumab&lupd_s=03%2F06%2F2018&rank=1 while we were told 2 years ago already that it would be discontinued
http://ir.genmab.com/releasedetail.cfm?releaseid=959265

[bibob]

The date is March 8 2016.- so old news.

[Mcjean]

Mere kaffe Bibob https://clinicaltrials.gov/ct2/show/NCT01920477?term=daratumumab OR ofatumumab OR tisotumab&lupd_s=03/06/2018&rank=1 E L har to links

[Bulder]

E L if you look at the changes in the study from may last year, you can see that they have changed from "terminated" to "active not recruiting". So Novartis decided to finish the study without genmab telling us about it.

[bibob]

MJ

[Bulder]

In other words: GSK terminated but Novartis resumed the study.

[E_L]

Bulder, i was reading that just the opposite; as if Novartis kept it alive longer without telling us and was wondering why they would have done that

[E_L]

ok, that is what i was reading

[E_L]

lol MJ

[Bulder]

If I was Bibob I would try with 3 Heineken.

[JKY_VH]

[Helge_LarsenPI-redaktør]

Samme mønster som seneste dage.Rolig handel, hvor A/B køber sig fra netto salg til nettokøb.
f

[Helge_LarsenPI-redaktør]

Et typisk "basedannelsesmønster".

[Helge_LarsenPI-redaktør]

Vil tro at et brud på årets top på 1.278 vil udløse et klart købssignal.

[Mcjean]

20 bogstaver Helge bravo, det kalder jeg et forum med høje lixtal, man får noget for pengene:-)

[Helge_LarsenPI-redaktør]

Tak...Jeg øver mig.

[Bulder]

Looking a bit closer into the ofa-study mentioned above, I can see that it was actually Novartis that terminated the study after acquiring the rights to ofa. They did that in May 2016. Nevertheless they resumed the study in May last year.

[gentogen]

AQpropos OFA så skrev de maj 16 på clinical trials "Novartis has acquired the rights to ofatumumab and terminated the OPV116910 and OPV117059 studies. This decision is not linked to any safety consideration". Antallet af patienter er det samme til slut som dengang, så de åbenbart valgt at følge patienterne i en ydvidet periode.